From a pharmacochemical perspective the current enemy of leprotics as well as could be expected advancements in the chemotherapy of sickness are talked about. Of the primary enemy of leprotics, which are utilized these days — dapsone, rifampicin, clofazimine, isoniazide, ethionamide and prothionamide — the component of activity, the fundamental issues in their application and conceivable outcomes to create improved variations are assessed. In view of the science of Mycobacterium leprae, the objective frameworks for new enemy of leprotics are distinguished. These frameworks incorporate the cell divider, the catabolism of receptive oxygen species, the digestion systems of carbon sources, the amino corrosive digestion and the take-up of iron. Two potential new lead structures from different fields, 4-quinolones and mycobacterial ribonucleotide reductase inhibitors are introduced.